Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture

Vikor Scientific Urine-IDTM is a molecular analysis technology which provides pathogen detection, quantification, and resistance gene identification. Urine-IDTM delivers its results through the technology platform Antibiotic Stewardship program (ABXAssist™), which provides results incorporating regional sensitivity and susceptibility patterns, medication costs, antibiotic spectrum of activity, and FDA guidance. This product aims to deliver prompt, patient-centered and value-based guidance to clinicians for antibiotic selection within 24 hours of delivery to testing facility. Proposed advantages of Vikor Scientific Urine-IDTM include: * Expeditious result (within 24 hours post-lab arrival) * Simultaneous detection of polymicrobial and monomicrobial infections * Identification of 49 most common antibiotic resistance genes * Provision of up-to-date regional sensitivity and susceptibility patterns * Provision of cost-sensitive treatment options and FDA guidance * Easy accessibility (mobile, web-portal and electronic health records Integration) This utility of this technology has yet to be investigated in a clinical study and could prove to be a viable alternative or adjunctive diagnostic tool to standard laboratory culture. Standard laboratory culture can take up to 7 days to return pathogen identification and antibiotic susceptibility, potentially delaying appropriate care and prolonging exposure to inappropriate empiric antibiotics. Our study aims to analyze the ability Vikor Scientific Urine-IDTM to improve time to identification of correct pathogen and accuracy of pathogen identification when compared to standard laboratory culture.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

1. Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to provide informed consent.
2. Age ≥ 18 years
3. Diagnosis of Non-Muscle Invasive Bladder Cancer (NMIBC)
4. Onset of cystitis or UTI symptoms within 7 days of Transurethral Resection of the Bladder Tumor (TURBT) or BCG installation
5. Ability to collect urine sample for analysis via standard laboratory culture and Vikor Scientific Urine-IDTM

Exclusion Criteria:

1. Inability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness provide informed consent
2. Age \<18 years
3. Diagnosis of Muscle-Invasive or metastatic bladder cancer
4. Onset of cystitis greater than 7 days following TURBT or BCG installation
5. Inability to provide sufficient urine for both standard laboratory culture and Vikor Scientific Urine-IDTM
6. Current prophylactic antibiotic use.